Literature DB >> 27002850

Medical management of glaucoma: focus on ophthalmologic drug delivery systems of timolol maleate.

Abhishek K Sah1, Preeti K Suresh1.   

Abstract

Eye is a vital organ of our body and any complication not only poses the risk of serious medical condition but also economic burden on the individual. Timolol maleate is one of the preferable therapeutic agents for the management of glaucoma. Globally, eye drops are among the most common and popular conventional formulations, but they are also associated with some limitations in terms of therapeutic response, bioavailability, dosing frequency and poor patient compliance. Present paper gives an overview of the drug delivery systems developed for management of glaucoma, advances and novel approaches with special emphasis on timolol drug delivery.

Entities:  

Keywords:  Eye; glaucoma; ocular; ocular drug delivery; ophthalmic; timolol; topical

Mesh:

Substances:

Year:  2016        PMID: 27002850     DOI: 10.3109/21691401.2016.1160917

Source DB:  PubMed          Journal:  Artif Cells Nanomed Biotechnol        ISSN: 2169-1401            Impact factor:   5.678


  3 in total

1.  A Topical Formulation of Melatoninergic Compounds Exerts Strong Hypotensive and Neuroprotective Effects in a Rat Model of Hypertensive Glaucoma.

Authors:  Massimo Dal Monte; Maurizio Cammalleri; Rosario Amato; Salvatore Pezzino; Roberta Corsaro; Paola Bagnoli; Dario Rusciano
Journal:  Int J Mol Sci       Date:  2020-12-04       Impact factor: 5.923

Review 2.  Topical Medication Therapy for Glaucoma and Ocular Hypertension.

Authors:  Tao Wang; Linlin Cao; Qikun Jiang; Tianhong Zhang
Journal:  Front Pharmacol       Date:  2021-12-01       Impact factor: 5.810

3.  The Effect of Polymers on Drug Release Kinetics in Nanoemulsion In Situ Gel Formulation.

Authors:  K Reeta Vijaya Rani; Sruthi Rajan; Mullaicharam Bhupathyraaj; R Krishna Priya; Nirmala Halligudi; Mohammad Abobakr Al-Ghazali; Sathvik B Sridhar; Javedh Shareef; Sabin Thomas; Saleem M Desai; Pandurang D Pol
Journal:  Polymers (Basel)       Date:  2022-01-21       Impact factor: 4.329

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.